Skip to Content
Important Safety Information
Prescribing Information
Sign up for Updates
Important Safety InformationPrescribing InformationFor PatientsSign up for Updates
EMFLAZA® (deflazacort) Home
  • Unmet Need
    • Muscle Function
    • Real-World Data
    • Long-Term Outcomes
    • Safety Profile
    • Weight & Behavior
  • Dosing & Administration
    • Switch Considerations
    • Prescription Start Form
  • Resources

Stay up to date on the latest news & clinical data

Register today to receive the latest on EMFLAZA for Duchenne muscular dystrophy.

All fields are required.

By clicking SUBMIT, you agree to the statement below and certify that you are at least 18 years of age and a US resident.

By submitting this form, you agree to allow PTC Therapeutics to collect the information provided and to receive product and disease-state information from PTC, our affiliates, service providers, and co-promotion partners by phone, email, or mail. PTC or third-party partners working on our behalf will not sell, rent, or otherwise distribute your name and any personally identifiable information. We may share your information with our partners in accordance with our Terms of Use and Privacy Policy.

You will have the opportunity to unsubscribe at any time.

Prescription Start Form
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Do Not Sell or Share My Personal Information
  • References
  • Site Map

This site is intended for US healthcare professionals.

PTC Cares™ is a trademark of PTC Therapeutics, Inc.
Emflaza® is a registered trademark of PTC Therapeutics, Inc.
© 2022 PTC Therapeutics, Inc. All Rights Reserved.

US-EMF-0297v3 12/22

PTC Therapeutics